Press releases

07.Jan 21

Market Notice 5/21– Last day of trading in Scandion Oncology A/S’s BTA

06.Jan 21

Scandion Oncology’s rights issue registered with the Danish Business Authority – BTAs are converted to shares
Scandion Oncology A/S ("Scandion" or the "Company") has carried out a rights ...

18.Dec 20

Letter from the CEO: Great progress in 2020 - we are ready for 2021!
Dear shareholder in Scandion Oncology, dear subscriber to Scandion Oncology N...

16.Dec 20

Scandion Oncology A/S – Flagging message
Scandion Oncology A/S ("Scandion Oncology" or "the Company") hereby announces...

15.Dec 20

Scandion Oncology: Supplement to previously published press release regarding the outcome of Scandion Oncology’s rights issue

15.Dec 20

SCANDION ONCOLOGY ANNOUNCES OUTCOME IN THE RIGHTS ISSUE
Scandion Oncology A/S ("Scandion" or the "Company") announces that the result...

24.Nov 20

Scandion Oncology publishes prospectus relating to the rights issue and announces the intention of changing listing venue to Nasdaq First North Growth Market Sweden
The Board of Directors of Scandion Oncology A/S ("Scandio...

19.Nov 20

Interim Report 1 January 2020 – 30 September 2020
Scandion Oncology A/S ("Scandion Oncology" or "the Company") hereby...

18.Nov 20

Market Notice 283/20 – Information regarding the rights issue from Scandion Oncology A/S

17.Nov 20

Correction of previously published press release regarding Scandion Oncology’s rights issue (trading in BTAs)
The press release of 16 November 2020 (released at 08:31:34) stated incorrect...

16.Nov 20

The Board of Directors of Scandion Oncology has resolved on a fully guaranteed rights issue of approximately SEK 236 million
The Board of Directors in Scandion Oncology A/S ("Scandion Oncology" or the "...

13.Nov 20

Correction: Scandion Oncology – Minutes of extraordinary general meeting
Erroneously the Press Release from 13 November, 2020 (released at 16:46:16) w...

13.Nov 20

Scandion Oncology – Minutes of extraordinary general meeting
which was held on: Friday 13 November 2020, at 2.00 PM at Scandion Oncology...

28.Oct 20

Scandion Oncology: Notice to convene Extraordinary General Meeting in Scandion Oncology A/S
Scandion Oncology A/S (CVR-no. 38 61 33 91) (the "Company") Extraordinary ...

28.Oct 20

Scandion Oncology A/S initiates its second clinical study with SCO-101
Scandion Oncology A/S is pleased to announce that its second clinical study w...

09.Oct 20

Scandion Oncology announces that the warrant exercise is registered at the Danish Companies Registration Office
Scandion Oncology A/S ("Scandion Oncology") today, October 9, 2020, announce ...

07.Oct 20

Scandion Oncology announces modified timelines for clinical studies
Scandion Oncology A/S ("Scandion Oncology") today announces modified timeline...

06.Oct 20

Scandion Oncology receives approximately MSEK 12.3 through successful warrant exercise
On Thursday, October 1, 2020, the exercise period for Scandion Oncology A/S (...

03.Oct 20

Scandion Oncology announces that it has been selected for the final round of MATWIN presentations
Scandion Oncology A/S ("Scandion Oncology") today announces that the company ...

02.Oct 20

Communique from the Extraordinary General Meeting of Scandion Oncology A/S
On Thursday 1 October 2020, the Extraordinary General Meeting of Scandion Onc...

29.Sep 20

Scandion Oncology’s management and Board of Directors have exercised their Scandion Oncology A/S series TO 1 warrants
Scandion Oncology announces that its management team and its Board of Directo...

28.Sep 20

Scandion Oncology receives final approval from the Danish Medicines Agency and Ethical Committee for start of a clinical trial in patients with pancreatic cancer
Scandion Oncology A/S ("Scandion Oncology") today announces that the company ...

25.Sep 20

Reminder to exercise Scandion Oncology A/S series TO 1 warrants
The subscription period for the series TO 1 warrants issued as part of Scandi...

23.Sep 20

Market Notice 237/20 – Last day of trading in Scandion Oncology A/S:s subscription option SCOL TO 1

16.Sep 20

Notice to Extraordinary General Meeting in Scandion Oncology A/S
The Board of Directors of Scandion Oncology A/S ("Scandion Oncology" or the"C...

16.Sep 20

Scandion Oncology strengthens executive leadership appointing Bo Rode Hansen as CEO and Nils Brünner as new CSO
Scandion Oncology appoints Bo Rode Hansen as new President & CEO and co-f...

10.Sep 20

The exercise period for warrants in Scandion Oncology A/S begins today
Today, September 10th, 2020, marks the beginning of the exercise period for t...

20.Aug 20

Scandion Oncology announces results from the next evaluable chemo-resistant colorectal cancer patient treated with SCO-101 and chemotherapy
Scandion Oncology A/S ("Scandion Oncology") reports that the next evaluable c...

20.Aug 20

Half-Year Report 1 January 2020 – 30 June 2020
Scandion Oncology A/S ("Scandion Oncology" or the "Company") hereby publishes...

01.Aug 20

Scandion Oncology announces that one of its founders, Saniona, has reduced its shareholding to below 10% of the total share amount
Scandion Oncology A/S ("Scandion Oncology") announces that Saniona has reduce...

31.Jul 20

Scandion Oncology drug SCO-101 potentiates the effect of chemotherapy in the first cohort of patients with chemo-resistant metastatic colorectal cancer
Scandion Oncology A/S ("Scandion Oncology") reports on data from the first co...

11.Jul 20

Scandion Oncology announces that the results of the 4 SCO-101 clinical phase I trials have been published in the journal "Basic & Clinical Pharmacology & Toxocology".
Scandion Oncology A/S ("Scandion Oncology") announces that the results from t...

03.Jul 20

Scandion Oncology announces that its Chairman of the Board has bought 6000 shares in Scandion Oncology
Scandion Oncology A/S ("Scandion Oncology") announces that its Chairman of th...

30.Jun 20

Scandion Oncology co-founders extend lock-up period
Scandion Oncology A/S ("Scandion Oncology") announces that its two co-founder...

22.Jun 20

Scandion Oncology announces that one of its founders, Saniona, has reduced its shareholding to below 15% of the total share amount
Scandion Oncology A/S ("Scandion Oncology") announces that Saniona has reduce...

16.Jun 20

Scandion Oncology has received a Eurostars grant of 800,000 EUR, shared with Erasmus Medical Centre, Rotterdam and 2cureX AB, for evaluating SCO-101 against antiestrogen resistance in breast cancer
Scandion Oncology A/S ("Scandion Oncology") is pleased to announce that it ha...

09.Jun 20

Scandion Oncology announces that the Clinical Trial Application for a pancreatic cancer study with chemotherapy and SCO-101 has been submitted to the Danish Medicines Agency and the Ethical Committee.
Scandion Oncology A/S ("Scandion Oncology") is pleased to announce that a Cli...

04.Jun 20

Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology
Lund, Sweden, June 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) a...

29.May 20

Communique from the Annual General Meeting of Scandion Oncology A/S
On May 27th, 2020, the Annual General Meeting of Scandion Oncology A/S ("Scan...

27.May 20

Scandion Oncology announces that the first patient has received treatment with SCO-101 in combination with FOLFIRI.
Scandion Oncology A/S ("Scandion Oncology") is pleased to announce that the f...

21.May 20

Interim report 1 January – 31 March 2020
Scandion Oncology A/S ("Scandion Oncology" or "the Company") hereby publishes...

15.May 20

Scandion Oncology’s drug SOM-001 demonstrates antibiotic activity in a mouse model infected with MRSA bacteria
Scandion Oncology has received positive results on the antibiotic in vivo eff...

11.May 20

Notice to Annual General Meeting in Scandion Oncology A/S
The Board of Directors of Scandion Oncology A/S ("Scandion Oncology" or the"C...

30.Apr 20

Scandion Oncology A/S Annual Report 2019 published
Scandion Oncology A/S ("Scandion Oncology") hereby publishes the Annual Repor...

24.Apr 20

Presentation of the ongoing Clinical Phase II trial at the AACR Virtual Annual Meeting
On April 27th CMO Peter Michael Vestlev will present at the AACR Virtual Annu...

26.Mar 20

Scandion Oncology CEO Newsletter (March 2020)
  Dear Scandion Oncology shareholder, Scandion Oncology wants to thank...

25.Mar 20

SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells
Scandion Oncology A/S ("Scandion Oncology") has published that combining SCO-...

23.Mar 20

Clinical development plans for SCO-101
The current Phase II clinical study with SCO-101 is treating a serious diseas...

20.Mar 20

Short delay of the antibiotic resistance data
Scandion Oncology A/S ("Scandion Oncology") hereby announces that the company...

10.Mar 20

Chairman, Vice-Chairman and CMO in Scandion Oncology A/S buy Company shares
Scandion Oncology A/S ("Scandion Oncology" or "the Company") today announces ...

09.Mar 20

Short delay in the clinical phase II study
Scandion Oncology A/S ("Scandion Oncology") informs about a short delay in th...

06.Mar 20

Publication on pre-clinical results with SCO-201
Scandion Oncology A/S ("Scandion Oncology") hereby announces that the company...

20.Feb 20

Year-end Report 1 January - 31 December 2019
Scandion Oncology A/S ("Scandion Oncology" or "the Company") hereby publishes...

19.Feb 20

Scandion Oncology receives DKK 5 million in soft money from Innovation Fund Denmark
Scandion Oncology A/S ("Scandion Oncology") hereby announces that the company...

03.Feb 20

Correction of dates for public information on Estimated Primary Completion and Primary Study Completion for a Clinical Phase II study
The clinical Phase II trial with drug resistant metastatic colorectal cancer ...

27.Jan 20

Scandion Oncology Newsletter 27 January, 2020

21.Jan 20

Scandion Oncology Newsletter 21st January, 2020
CEO Nils Brünner and Chairman of the Board Peter Høngaard, have now safely re...

14.Jan 20

Scandion Oncology News, January 2020

13.Jan 20

Scandion Oncology to attend the JP Morgan 38th Annual Healthcare Conference
Scandion Oncology A/S ("Scandion Oncology") Chief Executive Officer Nils Brün...

13.Jan 20

Peter Høngaard interviewed by Bio Stock
Bio Stock has interviewed the Peter Høngaard, Chairman of the Board, about th...

23.Dec 19

Scandion Oncology obtains approval from the Ethics Committee on Clinical Application for SCO-101 in patients with drug-resistant metastatic colorectal cancer
Scandion Oncology A/S ("Scandion Oncology") today announces that the company ...

16.Dec 19

Anti-bacterial treatment: Novel analogues with more than tenfold higher potency identified and technical issues with the in vivo experiments
Scandion Oncology A/S (“Scandion Oncology”) today announces that ...

29.Nov 19

Chairman and Vice-Chairman of the Board in Scandion Oncology A/S buy Company shares
Scandion Oncology A/S ("Scandion Oncology" or "the Company") today announces ...

29.Nov 19

Scandion Oncology receives final approval from the Danish Medicines Agency for start of clinical Phase II trial in patients with drug resistant metastatic colorectal cancer
Scandion Oncology A/S (“Scandion Oncology”) today announces that ...

21.Nov 19

Scandion Oncology CEO Newsletter November 2019
Dear Scandion Oncology shareholder,Being able to change drug resistance will ...

21.Nov 19

Interim Report 1 January 2019 - 30 September 2019
Scandion Oncology A/S (”Scandion Oncology” or the “Company&...

14.Oct 19

Scandion Oncology A/S receives EU-patent for SCO-101
Scandion Oncology A/S (“Scandion Oncology”) today announces that ...

01.Oct 19

Scandion Oncology applies for start of clinical Phase II trial in patients with metastatic colorectal cancer
Scandion Oncology A/S (“Scandion Oncology”) today announces that ...

01.Oct 19

In vivo animal data report on antibiotic resistance extended until mid-Q4 2019
Scandion Oncology A/S (“Scandion Oncology”) today announces that ...

01.Oct 19

Peter Høngaard new Chairman of the Board in Scandion Oncology
Scandion Oncology A/S (“Scandion Oncology”) today announces that ...

25.Sep 19

Scandion Oncology CEO Newsletter autumn 2019
Dear Scandion Oncology shareholder, Scandion Oncology is heading towards an ...

29.Aug 19

Flagging notification in Scandion Oncology A/S
Scandion Oncology A/S (”Scandion Oncology”) hereby announces that, in connect...

22.Aug 19

Half-Year Report 1 January 2019 - 30 June 2019
Scandion Oncology A/S (”Scandion Oncology” or the “Company”) hereby publishes...

21.Aug 19

Update on Q & A
Scandion Oncology wishes to make aware that we have published a new Q&A on Au...

05.Aug 19

First day of trading in TO 1 in Scandion Oncology
In June/July 2019, Scandion Oncology A/S (“Scandion Oncology”) conducted a ri...

26.Jul 19

Market Notice 210/19 - Last day of trading in Scandion Oncology A/S"s BTU

25.Jul 19

Last day of trading in BTU in Scandion Oncology
In June/July 2019, Scandion Oncology A/S (“Scandion Oncology”) conducted a ri...

12.Jul 19

Significantly oversubscribed rights issue in Scandion Oncology
On July 9, 2019, the subscription period in Scandion Oncology A/S’s ("Scandio...

27.Jun 19

Scandion Oncology has identified four clinical sites to take part in the planned Phase II clinical trial
Scandion Oncology A/S (“Scandion Oncology” or the “Company”) today announces ...

26.Jun 19

SCO-101 is successfully produced as tablets
Scandion Oncology A/S (”Scandion”) today announced that SCO-101 tablets have ...

20.Jun 19

The subscription period in Scandion Oncology"s rights issue begins today
Today, on the 20th of June, 2019, the subscription period for Scandion Oncolo...

17.Jun 19

Scandion Oncology A/S publishes prospectus in connection with rights issue
Prospectus relating to the rights issue in Scandion Oncology A/S (”Scandion O...

13.Jun 19

Market Notice 159/19 - Update - Information regarding the rights issue from Scandion Oncology A/S

11.Jun 19

Market Notice 152/19 - Information regarding the rights issue from Scandion Oncology A/S

11.Jun 19

Communique from the Extraordinary General Meeting in Scandion Oncology A/S
On June 11th, 2019, the Extraordinary General Meeting of Scandion Oncology A/...

06.Jun 19

Scandion Oncology appoints Chairman and Vice-Chairman of its Board of Directors
Scandion Oncology A/S (“Scandion Oncology”) hereby announces that Jørgen Bard...

03.Jun 19

Main shareholders signs lock-up agreements for 12 months
In connection with the announcement that the Board of Directors of Scandion O...

31.May 19

Communique from the Annual General Meeting of Scandion Oncology A/S
On May 29th, 2019, the Annual General Meeting of Scandion Oncology A/S (”Scan...

27.May 19

Notice of Extraordinary General Meeting in Scandion Oncology A/S
The Board of Directors of Scandion Oncology A/S (”Scandion Oncology” or the “...

27.May 19

The board of Scandion Oncology proposes a rights issue to increase the commercial potential for its drug candidates and to expand its drug pipeline
Scandion Oncology A/S (“Scandion Oncology” or ”the Company”) today announces ...

27.May 19

Interim report 1 January - 31 March 2019
Scandion Oncology A/S (”Scandion Oncology” or ”the Company”) hereby publishes...

21.May 19

Scandion Oncology A/S announces new date for publication of interim report January - March 2019
Scandion Oncology A/S would like to make use of the full window for releasing...

21.May 19

SCANDION ONCOLOGY A/S obtains "Intention to Grant" notice for SCO-101 from the European Patent Office (EPO)
SCANDION ONCOLOGY A/S is pleased to announce that the company has received an...

14.May 19

Notice to Annual General Meeting in Scandion Oncology A/S
The Board of Directors of Scandion Oncology A/S (”Scandion Oncology” or the“C...

03.May 19

Scandion Oncology A/S Annual Report 2018 published
Scandion Oncology A/S hereby publishes the Annual Report for 2018. The Annual...

16.Apr 19

Scandion Oncology signs collaboration agreement with University of Copenhagen regarding co-development of a class of drug candidates that reverts anti-cancer drug resistance
Scandion Oncology A/S (”Scandion” or ”the Company”) announces today that the ...

08.Apr 19

Scandion Oncology obtains EU Funding for SCO-101 in drug resistant breast cancer patients
Scandion Oncology A/S (”Scandion” or ”the Company”) announces today that the ...

26.Mar 19

Scandion Oncology A/S reports successful meeting with Danish Medicines Agency regarding clinical development of SCO-101
Scandion Oncology and The Danish Medicines Agency have had a very positive ...

18.Mar 19

Scandion Oncology Signs Contract with Solural Pharma to Formulate SCO-101 Tablets for Clinical Phase II Trial
Scandion Oncology A/S and Solural Pharma ApS have entered into an agreement...

11.Mar 19

Scandion Oncology A/S Obtains Positive Preclinical Results in Antibiotic Resistance
Scandion Oncology A/S (Scandion Oncology) hereby announces that Scandion Onco...

11.Mar 19

Presentation video in relation to year-end report
Scandion Oncology has made two videos to present the company and the basic co...

22.Feb 19

Year End Report for 2018
Scandion Oncology has published the Year End Report for 2018. The Press Relea...

21.Feb 19

Year-end Report 1 January - 31 December 2018
Scandion Oncology A/S (”Scandion Oncology” or ”the Company”) hereby publishes...

30.Dec 18

Senior executives increase their holdings in Scandion Oncology
The increase of shares of senior executives in Scandion Oncology can be viewe...

21.Dec 18

Disclosure notice

21.Dec 18

Senior executives increase their holdings in Scandion Oncology A/S
Scandion Oncology A/S ("Scandion Oncology") today announces that the Chairman...

14.Dec 18

Scandion Oncology informs on the selection of collaborator for the Boost4Health Internationalisation grant
Scandion Oncology A/S (“Scandion Oncology”) today announces that the company ...

22.Nov 18

Interim Report Q3 2018
Scandion Oncology A/S (”Scandion Oncology”) herby reports interim report for ...

13.Nov 18

Scandion Oncology to receive EU support to boost international development
Scandion Oncology A/S has been granted an Impact Voucher of 14.999 EUR from B...

08.Nov 18

First day of trading in Scandion Oncology A/S shares on Spotlight Stock Market
Today, November 8, 2018, is the first day of trading in Scandion Oncology A/S...

01.Nov 18

Marknadsmeddelande 260/18- Scandion Oncology A/S noteras på Spotlight Stock Market den 8 november2018
Första handelsdag på Spotlight Stock Market för Scandion Oncology A/S aktie ä...

23.Oct 18

Scandion Oncology A/S new share issue oversubscribed
On October 18, 2018, the subscription period for Scandion Oncology A/S’s ("Sc...

04.Oct 18

Idag inleds teckningstiden i Scandion Oncology A/S nyemission inför planerad notering på Spotlight Stock Market
Idag, den 4 oktober 2018, inleds teckningstiden i Scandion Oncology A/S ("Sca...

04.Oct 18

The subscription period for Scandion Oncology A/S new share issue begins today
Today, October 4, 2018, the subscription period for Scandion Oncology A/S ("S...

01.Oct 18

Scandion Oncology A/S approved for listing at Spotlight Stock Market
Today, Scandion Oncology A/S (“Scandion Oncology”) announces that the company...

01.Oct 18

Scandion Oncology A/S är godkänt för notering på Spotlight Stock Market
Scandion Oncology A/S (“Scandion Oncology”) meddelar idag, den 1 oktober 2018...

06.Aug 18

Scandion Oncology A/S signs agreement with Sedermera Fondkommission AB regarding an Initial Public Offering at Spotlight Stock Market.

Scandion Oncology A/S hereby announces that an agreement has been signed w...

19.Dec 17

Saniona Spin-Out, Scandion Oncology Raises DKK 2 Million and Prepares for a Potential Public Listing
Saniona, a leading biotech company in the field of ion channels, today announ...

17.May 17

New Saniona spinout focused on cancer therapy
Scandion Oncology, a spinout from the biotech company Saniona, offers experie...

15.May 17

Saniona satser på spinout-virksomheder
Det danske biotekselskab Saniona har netop etableret sin tredje spinout-virks...

14.May 17

Nyt Saniona-spinout har fokus på kræft
Scandion Oncology, der er en spinout-virksomhed fra biotekselskabet Saniona, ...

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union
Privacy and Cookie Policy